Overview

• Asabys Partners leads the extension and its managing partner, Josep Ll. Sanfeliu, joins SafeHeal’s board.
• The raise extends an oversubscribed €35 million Series C, with participation from Sofinnova, Solar Eclipse, Gideon Strategic Partners, Polis, and M&L Healthcare, and an increased commitment from Gideon.
• Colovac is a temporary endoluminal bypass designed to reduce fecal contact at the anastomosis, typically stays in place for about 10 days, and is removed endoscopically to avoid a second surgery.
• In the United States, Colovac is limited by federal law to investigational use and is not available for sale.
• A trade outlet reports FDA Breakthrough Device designation and EU MDR marketing approval for Colovac, a claim not confirmed in the company’s announcement.